The current Covid-19 pandemic has exhausted supplies of personal protective equipment. Avadim Health’s hospital brand, Theraworx Protect, is filling gaps across multiple industries, including national and regional drug and grocery chains to help defend the retail pharmacist. Theraworx Protect has been tested and studied by some of our most respected institutions, including Stanford, Duke University, University of Florida Shands, UNC Chapel Hill, and more. It has been studied in patients with many different challenging medical conditions, and because of the current crisis, Theraworx Protect has been recruited out of the hospital setting to serve office-based physicians, nurses, departments of transportation employees, federal agents, emergency service employees, border personnel, and national delivery employee corporations nationwide.

In 2019, Theraworx Protect was used to help reduce risks associated with nosocomial infections in more than 4 million ICU patients. The hygiene formulation has also been chosen by many academic teaching hospitals as part of the clinical bundles indicated to prevent central–line bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), Clostridium difficile infections, and ventilator-associated pneumonia (VAP).

More than 20 of the Theraworx Protect clinical studies have been peer-reviewed. Theraworx Protect is safe for the face and T-zone (around the eyes, nose and mouth), which is the primary zone of viral entry. The CDC recommends frequent hand and facial cleansing as a first line of defense, and Theraworx Protect can help the healthcare professional add a needed layer of cleansing beyond hand hygiene.

For clinical inquiries about Theraworx Protect, visit

About Avadim Health, Inc.:
Avadim is a high-growth healthcare and wellness company that sells topical products to improve immune health, neuromuscular health and skin barrier health. Using its proprietary platform, called the Bionome Engineered Platform, Avadim has developed products that target the institutional care and self-care markets. The company believes there is significant unmet global demand for nonprescription options, such as its products, as an alternative to drugs that are more expensive or potentially addictive and can have long-term detrimental implications for health and society. Avadim’s mission, “Discovering New Ways to Care,” represents its strong belief that by harnessing the innate power of the skin’s ecosystem, it can improve the health of individuals with products that address current societal challenges, including access to care, affordability, drug resistance and addiction. Avadim uses an evidence-based approach to develop, test and market its products. This clinical evidence contributed to the successful registration of several of its products for Medicare and Medicaid reimbursement, and enables the sales teams to serve customers across the full continuum of care, from institutional care to self-care, including in hospitals, long-term care facilities, closed provider pharmacies, physician offices and retail pharmacies.

Consumer Investors:
John Mills
[email protected]

Healthcare Investors:
Stephanie Carrington
[email protected]

Sean Leous
[email protected]